During the interim analysis of a double-blind RCT comparing a novel tuberculosis regimen with standard therapy in 800 Indian TB patients, the Data Safety Monitoring Board (DSMB) observes a statistically significant difference in cure rates (new regimen: 92%, standard: 85%, p = 0.008) at 50% enrollment. The DSMB chair asks: what is the most appropriate next step?